Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 15;35(14):2399-2401.
doi: 10.1097/QAD.0000000000003017.

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Jake A Ruddy  1 , Brian J Boyarsky  1 , Justin R Bailey  2 , Andrew H Karaba  2 , Jacqueline M Garonzik-Wang  1 , Dorry L Segev  1   3 , Christine M Durand  2 , William A Werbel  2
Affiliations

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Jake A Ruddy et al. AIDS. .

Abstract

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

PubMed Disclaimer

Conflict of interest statement

D.L.S. has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific. C.M.D. has the following financial disclosures: research grants from GlaxoSmithKline and Abbvie and served on a grant review committee for Gilead Sciences. The other authors have no conflicts of interest.

This research was made possible with generous support of the Ben-Dov family. This work was supported by grant number F32DK124941 (B.J.B.), and K23DK115908 (J.G.W.) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K24AI144954 (D.L.S.) and U01AI134591 and U01AI138897 (C.M.D., D.L.S.) from the National Institute of Allergy and Infectious Diseases (NIAID), and by a grant from the Transplantation and Immunology Research Network of the American Society of Transplantation (W.A.W.). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

Figures

Fig. 1.
Fig. 1.. Anti-SARS-CoV-2 receptor binding domain antibody titres of people with HIV on antiretroviral therapy who underwent two-dose SARS-CoV-2 mRNA vaccination.
T1 (titre 1, n = 10) and T2 (titre 2, n = 14) denote anti SARS-CoV-2 RBD titres measured before and 1 month after the second dose of SARS-CoV-2 mRNA vaccination; lines indicate the change in an individual participant’s titre. Assay results could range from <0.4 to >250 U/ml.
See this image and copyright information in PMC

References

    1. Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: a systematic review. AIDS Behav 2021; 25:85–92. - PMC - PubMed
    1. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open 2021; 4:e2037069. - PMC - PubMed
    1. Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2021; 72:340–350. - PMC - PubMed
    1. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2021; 384:80–82. - PMC - PubMed
    1. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 383:2439–2450. - PMC - PubMed

Publication types